Healthcare provider profile · identity verified

Daniel Feleke, MD

Family Practice · BROCKTON, MA · NPI 1598905630

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	879	242
Lisinopril	Lisinopril	408	116
Amlodipine Besylate	Amlodipine Besylate	340	96
Omeprazole	Omeprazole	285	72
Hydrochlorothiazide	Hydrochlorothiazide	276	85
Levothyroxine Sodium	Levothyroxine Sodium	227	57
Losartan Potassium	Losartan Potassium	208	62
Metformin Hcl	Metformin Hcl	208	55
Metoprolol Succinate	Metoprolol Succinate	201	57
Gabapentin	Gabapentin	188	41
Simvastatin	Simvastatin	155	37
Albuterol Sulfate Hfa	Albuterol Sulfate	150	49
Fluticasone Propionate	Fluticasone Propionate	142	53
Jardiance	Empagliflozin	127	27
Tamsulosin Hcl	Tamsulosin Hcl	126	31
Pantoprazole Sodium	Pantoprazole Sodium	115	27
Trulicity	Dulaglutide	105	16
Ozempic	Semaglutide	100	16
Fluoxetine Hcl	Fluoxetine Hcl	96	18
Trazodone Hcl	Trazodone Hcl	90	22
Furosemide	Furosemide	88	35
Sertraline Hcl	Sertraline Hcl	87	19
Famotidine	Famotidine	86	21
Atenolol	Atenolol	85	22
Carvedilol	Carvedilol	85	22
Allopurinol	Allopurinol	75	19
Glipizide Er	Glipizide	75	21
Rosuvastatin Calcium	Rosuvastatin Calcium	75	27
Ezetimibe	Ezetimibe	73	24
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	71	17
Eliquis	Apixaban	70	19
Citalopram Hbr	Citalopram Hydrobromide	68	18
Lorazepam	Lorazepam	66	14
Olmesartan Medoxomil	Olmesartan Medoxomil	66	17
Pravastatin Sodium	Pravastatin Sodium	65	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	18
Bupropion Xl	Bupropion Hcl	59	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	57	suppressed
Potassium Chloride	Potassium Chloride	54	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	53	15
Alprazolam	Alprazolam	51	suppressed
Duloxetine Hcl	Duloxetine Hcl	50	14
Ibuprofen	Ibuprofen	49	18
Ventolin Hfa	Albuterol Sulfate	47	suppressed
Hydralazine Hcl	Hydralazine Hcl	45	suppressed
Metformin Hcl Er	Metformin Hcl	45	17
Metoprolol Tartrate	Metoprolol Tartrate	45	12
Prednisone	Prednisone	43	25
Mounjaro	Tirzepatide	42	suppressed
Finasteride	Finasteride	39	12
Fenofibrate	Fenofibrate	38	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	11
Tramadol Hcl	Tramadol Hcl	37	11
Clopidogrel	Clopidogrel Bisulfate	35	12
Escitalopram Oxalate	Escitalopram Oxalate	35	12
Pregabalin	Pregabalin	35	suppressed
Baclofen	Baclofen	33	suppressed
Clonazepam	Clonazepam	33	suppressed
Ondansetron Hcl	Ondansetron Hcl	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	11
Levetiracetam	Levetiracetam	28	suppressed
Lidocaine	Lidocaine	28	suppressed
Montelukast Sodium	Montelukast Sodium	28	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	26
Incruse Ellipta	Umeclidinium Bromide	27	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Glipizide	Glipizide	25	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Valsartan	Valsartan	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	19	suppressed
Glimepiride	Glimepiride	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Constulose	Lactulose	16	suppressed
Linzess	Linaclotide	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Ondansetron Odt	Ondansetron	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Nystatin	Nystatin	13	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Naproxen	Naproxen	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Testosterone	Testosterone	12	suppressed
Topiramate	Topiramate	12	suppressed
Digoxin	Digoxin	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error